Vertex Pharmaceuticals (VRTX) is a publicly traded Healthcare sector company. As of September 23, 2026, VRTX trades at $516.13 with a market cap of $129.45B and a P/E ratio of 30.16. VRTX moved +0.83% today. Year to date, VRTX is +13.59%; over the trailing twelve months it is +34.42%. Its 52-week range spans $362.50 to $560.25. Analyst consensus is strong buy with an average price target of $572.77. Rallies surfaces VRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for VRTX, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $516.13 |
| Market Cap | $129.45B |
| P/E Ratio | 30.16 |
| EPS | $17.33 |
| Dividend Yield | 0.00% |
| 52-Week High | $560.25 |
| 52-Week Low | $362.50 |
| Volume | 1.07M |
| Avg Volume | 0 |
| Revenue (TTM) | $12.59B |
| Net Income | $4.41B |
| Gross Margin | 86.00% |
26 analysts cover VRTX: 0 strong buy, 21 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $572.77.